Form 4: Karyopharm Director Barry Greene Reports RSU Award

Barry E. Greene, a Director at Karyopharm Therapeutics Inc., has reported the acquisition of 15,508 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

Summary

• Director Barry E. Greene was awarded 15,508 restricted stock units (RSUs) on May 21, 2026.
• These RSUs are part of the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan.
• The RSUs vest fully on May 21, 2027.
• Delivery of the shares underlying the RSUs is deferred until the director's separation from service or a change-in-control event.
• The reported amounts reflect a one-for-fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity award to a director and does not contain new financial performance data or strategic shifts.

Positives

• Award of restricted stock units to a director, indicating continued incentive and alignment with company performance.
• The RSU award vests fully, suggesting a commitment to long-term retention and performance.

Risks

• The value of the RSUs is subject to the future stock price performance of Karyopharm Therapeutics Inc.
• Delivery of shares is contingent on separation from service or a change-in-control event, which introduces uncertainty regarding the timing of actual share receipt.

Future Outlook

The future outlook for the RSUs is tied to the company's stock performance and the occurrence of specific events such as separation from service or a change-in-control.

Industry Context

StockSavvy.ai notes that the issuance of equity awards like RSUs to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain key talent and align their interests with shareholders, especially during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The RSU award represents potential future dilution, but also signals continued commitment from a director.
• Employees: The RSU award is part of the company's broader equity incentive strategy, which can impact employee morale and retention.
• Director Barry E. Greene: Direct financial benefit contingent on continued service and company events.

Next Steps

• Delivery of shares upon separation from service or a change-in-control event.
• Continued service by Director Barry E. Greene.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Form 4, SEC Filing, Barry Greene, Director, Restricted Stock Units, RSU, Equity Incentive Plan, Stock Split